Skip to main content
. 2014 Mar 28;459(Pt 2):275–287. doi: 10.1042/BJ20131344

Figure 6. Prior IGF-1 treatment down-regulates AMPK activation by A769662 in PTEN-null tumour cell lines.

Figure 6

(A) Glioblastoma (DBTRG-05MG) cells were incubated for 20 min with or without MK2206 (3 μM), followed by 60 min with or without A769662 (300 μM). Lysates were then analysed for AMPK activity. Results are means±S.E.M. (n=2); ***P<0.001; **P<0.01. (B) Analysis of the samples from (A) by Western blotting using the indicated antibodies (duplicate dishes). (C) WT PTEN or a phosphatase-inactive (C124S) mutant were expressed in DBTRG-05MG cells using lentiviral vectors, and the effects of A769662 tested as in (A). Results are means±S.E.M. (n=2 for WT PTEN, n=4 for C124S PTEN); ***P<0.001; **P<0.01. (D) Analysis of the samples from (C) by Western blotting using the antibodies shown (duplicate dishes). (E and F) Glioblastoma (U373-MG) cells were incubated and analysed as in (A and B). (G and H) Breast cancer (MDA-MB-468) cells were incubated and analysed as in (A and B). For (E) and (G), results are means±S.E.M. (n=2); ***P<0.001; **P<0.01; *P<0.05.